Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT01217229

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01217229. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.The primary objective of this study is to evaluate the efficacy, as measured by overall response rate, of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin lymphoma (HL). Secondary objectives include safety, the duration of response, the disease control rate, progression free survival, and how the drug affects your body.

Study identification

NCT ID: NCT01217229
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 20 participants

Conditions and interventions

Conditions

Hodgkin Lymphoma

Interventions

PLX3397 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 3, 2011 (Actual)
Primary completion: Apr 26, 2012 (Actual)
Completion: Apr 26, 2012 (Actual)
Last update posted: Jun 30, 2020

2011 – 2012

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
UCLA Jonsson Comprehensive Cancer Center	Los Angeles	California	90095	—
Northwestern University, The Robert H Lurie Comprehensive Cancer Center	Chicago	Illinois	60611	—
Mayo Clinic	Rochester	Minnesota	55905	—
Nebraska Medical Center	Omaha	Nebraska	68198	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01217229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 30, 2020 · Synced Nov 14, 2026